ODI Pharma AB: Publication of interim report report Q1 2023/2024
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 – September 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2023-07-01 – 2023-09-30) The Group's net sales amounted to SEK 528 206 (28 006). The Group's loss after financial items amounted to SEK -1 442 544 (-1 598 205). Result per share amounted to SEK -0.09 (-0.11).* The solidity as of 2023-09-30 was 15% (90%).** * The Company’s result per share: The